99% Purity Cyproterone Tablet Pharmaceutical Cyproterone Acetate Powder Raw Powder Cyproterone

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Cyproterone
• Product Name: Cyproterone Acetate
• Appearance: White or off-White Crystalline Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Contraceptive
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 427-51-0
• Mf: C24h29clo4
• MW: 416.94
• Density: 1.0677 (Rough Estimate)
• Melting Point: 200-201 C
• Boiling Point: 528.8 C (Rough Estimate)
• Refractive Index: 1.582
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500 Kg/Month

Product Description

99% Purity Cyproterone Tablet Pharmaceutical Cyproterone Acetate powder Raw Powder Cyproterone

 

Product Description

Product Details

Product Name	Cyproterone acetate
Appearance	White or off-white crystalline powder
CAS No.	427-51-0
MF	C24H29ClO4
MW	416.94

Cyproterone acetate (CPA) is an androgen receptor antagonist.  It binds to human androgen receptors (Ki = 14 nM) and inhibits dihydrotestosterone-induced androgen receptor activation in CV-1 cells (IC50 = 26 nM).  CPA (30 mg/kg) decreases ventral prostate weight in castrated immature rats.  It also suppresses accessory sexual glands and fertility in adult male rats when administered at a dose of 10 mg/kg.  CPA (0.3 μM) also induces apoptosis in primary adult female rat hepatocytes.  Formulations containing cyproterone acetate have been used in the treatment of androgenization in females.

Application & Function

Cyproterone acetate is a synthetic steroidal antiandrogen, progestin, and antigonadotropin.
Cyproterone acetate is primarily used in the treatment of androgen-related conditions by virtue of its ability to suppress androgenic activity in the body, an effect which it mediates by preventing endogenous androgens from interacting with the androgen receptor and by suppressing androgenbiosynthesis.
CPA has been approved for the treatment of prostate cancer, precocious puberty, androgen-related dermatological conditions (such as acne, seborrhea, hirsutism, and androgenic alopecia), and to reduce sex drive in sex offenders.  Combination formulations of CPA with ethinyl estradiol (a formulation sometimes referred to as co-cyprindiol) have been available as contraceptives since 1997.
Other uses of CPA include the treatment of benign prostatic hyperplasia, priapism, hypersexuality, paraphilias, hot flashes, and hyperandrogenism in women.

Specification